Effect of collagen and fish oil in burn

Effect of hydrolyzed collagen alone, or in combination with fish oil on wound healing, metabolic disorders and adipose derived peptides in patients with burn

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090901002394N42

Enrollment

Registered

2019-03-15

Start date

2019-04-04

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Burns. Condition 2: Burns. Condition 3: Burns. Burn and corrosion of trunk Burn and corrosion of shoulder and upper limb, except wrist and hand Burn and corrosion of lower limb, except ankle and foot

Interventions

Intervention 1: Intervention group 1: Daily intake of 40 gr hydrolyzed collagen for 4 weeks. Intervention 2: Intervention group 2: Daily intake of 40 gr hydrolyzed collagen plus 10 ml fish oil for 4 w

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with 20-45% total body surface area burn Patients with burn degree of 2 (deep) or 3 Age 18-60 years The ability of oral intake of foods

Exclusion criteria

Exclusion criteria: History of any metabolic or chronic diseases such as diabetes, cardiovascular diseases, organ failures, and etc. Body mass index < 18.5 kg/m2 History of allergy or intolerance to protein products Pregnant women Drug and alcohol addicts

Design outcomes

Primary

Measure	Time frame
Pre-albumin serum concentration. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: Biochemical assay.	—

Secondary

Measure	Time frame
Body weight. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: Body scale.;Body mass index. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: Calculation based on the relevant formula.;Duration of hospital stay. Timepoint: Time of discharge. Method of measurement: Patient's records.;Wound healing. Timepoint: End of weeks 2 and 4. Method of measurement: Observation.;High-sensitivity C-reactive Protein serum concentration. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: ELISA.;Transforming growth factor beta serum concentration. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: ELISA.;Adiponectin serum concentration. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: ELISA.;Fasting blood glucose concentration. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: Biochemical assay.;Fasting insulin serum concentration. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: ELISA.;Homeostasis model assessment of insulin resistance. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: Calculation based on the relevant formula.;Daily energy intake. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: 24-h dietary recall.;Daily protein intake. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: 24-h dietary recall.;Fibroblast growth factor 21 serum concentration. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: ELISA.;Neuregulin 4 serum concentration. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: ELISA.;Vancouver Scar Scale. Timepoint: End of week 4. Method of measurement: Scoring based on a questionnaire.	—

Measure

Time frame

Body weight. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: Body scale.;Body mass index. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: Calculation based on the relevant formula.;Duration of hospital stay. Timepoint: Time of discharge. Method of measurement: Patient's records.;Wound healing. Timepoint: End of weeks 2 and 4. Method of measurement: Observation.;High-sensitivity C-reactive Protein serum concentration. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: ELISA.;Transforming growth factor beta serum concentration. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: ELISA.;Adiponectin serum concentration. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: ELISA.;Fasting blood glucose concentration. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: Biochemical assay.;Fasting insulin serum concentration. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: ELISA.;Homeostasis model assessment of insulin resistance. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: Calculation based on the relevant formula.;Daily energy intake. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: 24-h dietary recall.;Daily protein intake. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: 24-h dietary recall.;Fibroblast growth factor 21 serum concentration. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: ELISA.;Neuregulin 4 serum concentration. Timepoint: Baseline, end of weeks 2 and 3. Method of measurement: ELISA.;Vancouver Scar Scale. Timepoint: End of week 4. Method of measurement: Scoring based on a questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShima Jazayeri

Iran University of Medical Sciences

sjazayeri@razi.tums.ac.ir+98 21 8670 4805

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 12, 2026